2021年4月19日 · Transplant-associated thrombotic microangiopathy (TA-TMA) resides within a spectrum of transplant-associated endothelial cell activation syndromes, including...

2023年7月26日 · Carfilzomib is an effective therapy for multiple myeloma. However, carfilzomib-induced thrombotic microangiopathy (TMA) has emerged as a potential severe complication, characterised by...

2015年1月22日 · Syndromes of thrombotic microangiopathy (TMA), defined by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis with characteristic vessel wall abnormalities, have multiple etiologies. 1 Many patients with TMA have been reported to have a drug-induced etiology and many different drugs and other substances, including ...

2023年4月14日 · Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a severe and potentially life-threatening complication. HSCT-TMA is often...

2019年3月1日 · The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm uses two biomarkers, ST2 and REG3α, measured on day 7 following allogenic stem cell transplant to predict aGVHD and 6-month NRM. This algorithm defines two risk groups denoted Ann Arbor high risk and low risk.

2025年3月6日 · Transplant-associated thrombotic microangiopathy (TA-TMA) is an endothelial dysfunction syndrome observed after allogeneic hematopoietic cell transplant (alloHCT). Our aim was to externally validate the impact of high-risk features on the clinical outcomes of adult patients meeting the updated TA-TM …

2016年9月2日 · Transplant-associated thrombotic microangiopathy (TA-TMA) is a multifactorial disorder caused by systemic vascular endothelial injury that can be triggered by several mechanisms during the transplant process. Thrombotic microangiopathy may affect multiple systems and occurs in ~30% of patients under …

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) is a fatal post-transplant complication. It has a high mortality rate and worse prognosis, but treatment strategies remain controversial. We screened 6 out of 3453 studies on the treatment of TA-TMA.

2023年3月9日 · TA-TMA manifests as thrombotic microangiopathy: thrombocytopenia, microangiopathic hemolytic anemia, and organ dysfunction. Clinical symptoms of TA-TMA include renal insufficiency, serositis, hypertension, pulmonary hypertension, diffuse alveolar hemorrhage, posterior reversible encephalopathy syndrome, and gastrointestinal bleeding (4,5).

Thrombotic microangiopathy (TMA), a pathologic description, is characterized by a clinical presentation with thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and organ injury (1,2).